Drug Trial Radar · NCT07763054
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Aug 31, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Haikou Affiliated Hospital of Central South University Xiangya School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 13, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, single-arm, observational clinical study evaluating the efficacy and safety of low-dose liposomal amphotericin B (50 mg/day, intravenous, once daily) for the prevention of invasive fungal infections in adult patients (aged 18-75 years) with hematological malignancies who develop prolonged neutropenia (absolute neutrophil count ≤0.5×10\^9/L, expected to last \>7 days) and are at high risk for invasive fungal disease. Participants are those who, per the treating physician's routine clinical decision, have been initiated on liposomal amphotericin B prophylaxis at 50 mg/day due to intolerance or toxicity to other antifungal agents. The primary outcome is the incidence of proven or probable invasive fungal disease. Secondary outcomes include incidence of pneumonia, persistent unexplained fever \>4 days, use of additional systemic antifungal therapy, and adverse events. A total of 30 participants will be enrolled. Data will be collected at baseline, during treatment, and within 7 days after treatment completion.
Conditions
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Myelodysplastic Syndrome
- Lymphoma
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Neutropenia
- ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Invasive Fungal Infections
Interventions
Liposomal Amphotericin BDrug
Liposomal amphotericin B at 50 mg/day, administered intravenously once daily, for antifungal prophylaxis in patients with prolonged neutropenia. Liposomal amphotericin B is a broad-spectrum polyene antifungal agent with activity against most pathogenic fungi, including Candida, Aspergillus, and Mucorales species. The liposomal formulation reduces nephrotoxicity compared to conventional amphotericin B deoxycholate while maintaining equivalent antifungal activity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Proven or Probable Invasive Fungal DiseaseTime frame: From baseline to 7 days after the end of antifungal prophylaxis treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Hainan, Hainan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.